Genprex, Inc. 8-K

What Happened

• On May 26, 2026 Genprex, Inc. issued a press release and filed an 8-K reporting that a research collaborators’ abstract was published at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract reports clinical biomarker data from patients treated with Genprex’s lead gene therapy candidate, REQORSA (quaratusugene ozeplasmid), which delivers a plasmid encoding the TUSC2 tumor suppressor.
• The analysis included tumor samples and progression-free survival (PFS) data from 18 patients across three Acclaim trials (Acclaim-1: 6 NSCLC with osimertinib; Acclaim-2: 1 NSCLC with pembrolizumab; Acclaim-3: 11 SCLC with atezolizumab). In non-small cell lung cancer (NSCLC) patients, Trop-2 H-scores >100 correlated with longer PFS (p = 0.05) and PTEN H-scores <100 correlated with longer PFS (p = 0.03). SCLC patients had uniformly low Trop-2 and no PTEN–PFS correlation (p = 0.53). Additional analysis showed 3+ Trop-2 staining in NSCLC trended with longer PFS (p = 0.053).

Key Details

• Data source: abstract titled “Predictive biomarkers for PFS in patients receiving quaratusugene ozeplasmid” presented at ASCO 2026; filing date May 26, 2026.
• Sample size: 18 total patients (6 NSCLC in Acclaim-1, 1 NSCLC in Acclaim-2, 11 SCLC in Acclaim-3).
• Biomarker thresholds and significance: Trop-2 H-score >100 (NSCLC) p=0.05; PTEN H-score <100 (NSCLC) p=0.03; 3+ Trop-2 staining trend p=0.053.
• Methods: tumor protein expression measured by IHC (Trop-2 antibody BSB148, PTEN antibody 138G6) with H-scores used to quantify staining.

Why It Matters

• For investors, these published biomarker correlations are potentially material because they could help identify which NSCLC patients are most likely to benefit from REQORSA, inform patient selection for future trials, and support a precision-medicine development path.
• The dataset is small (18 patients) and results are preliminary; the company’s 8-K includes standard forward-looking cautionary language that outcomes and timelines remain uncertain.